Panitumumab outcome by tumour location analysis
Study 181: baseline characteristics
•
Boeckx N, et al. Ann Oncol 2016;27(Suppl 6):abstract 89P (and poster).
WT
RAS
Panitumumab + FOLFIRI
FOLFIRI
Left
(n = 150)
Right
(n = 31)
Left
(n = 148)
Right
(n = 39)
ECOG PS, %
0
1
2
52.0
44.0
4.0
35.5
54.8
9.7
52.0
41.2
6.8
48.7
43.6
7.7
Prior adjuvant, %
No
Yes
76.7
20.7
67.7
29.0
83.8
16.2
82.1
15.4
BRAF
status, %
Mutant
Wild type
Failure
4.7
95.3
-
29.0
71.0
-
2.7
97.3
-
33.3
66.7
-
Metastatic sites, %
Liver + other
Liver only
Other only
68.0
19.3
12.7
64.5
9.7
25.8
60.8
24.3
14.9
69.2
12.8
17.9
Median age, years
61
60
60
62
